Pharmaceutical safety professionals are welcome to register to participate and see the full content
What is drug Safety?
A video introduction from Uppsala Monitoring Center
DMA- Many more doctors in Denmark apply for permission to cooperate with the industry: In recent years, we have seen... http://t.co/4RuUJQ6j
DMA- Danish Pharmacovigilance Update, 19 January 2012: In this issue of Danish Pharmacovigilance Update: * Patients... http://t.co/SOPBBD3h
DMA- Review concluded regarding general reimbursement for Xarelto®: The Danish Medicines Agency has completed its... http://t.co/uaHRGyhw
DMA- Danish translation of the PhVWP's recommendation for the product information of Strattera (atomoxetine): The... http://t.co/GNM2lrb8
DMA- Problems with ASR hip implants from DePuy: The ASR hip implants from the company DePuy were recalled from the... http://t.co/hkQXGYl4
United Kingdom http://t.co/b0wkGg6h
FDA- Tysabri (natalizumab): Drug Safety Communication - New Risk Factor for Progressive Multifocal... http://t.co/FKNBCBIk
European Medicines Agency and European Food Safety Authority commit to greater co-operation: http://t.co/UDxH9iVW
Public consultation open on concept paper on #pharmacogenomics in evaluation of authorised medicines: http://t.co/HFJulUyu
European Medicines Agency recommends approval of new medicine for #Cushing’s disease http://t.co/LCL7SZtu
EMA recommends suspension of marketing authorisations for #meprobamate-containing medicines in the EU http://t.co/E7oNGdzt
Meeting highlights from the #CHMP 16-19 January 2012 http://t.co/8A4QEZc3
European Medicines Agency releases guideline on #biosimilar #interferon beta for public consultation: http://t.co/r1JMHGHx
European Medicines Agency starts review of #Gilenya (#fingolimod) http://t.co/1mKLrgNY
FDA approves Inlyta to treat patients with a type of advanced kidney cancer. http://t.co/vErKV3xu
New Drug Safety Podcast for Healthcare Professionals: New risk factor for PML associated with Tysabri. http://t.co/Gymql3SR
En Espanol: Safety Communication: Update: Preliminary findings from ongoing investigations of CardioGen-82. http://t.co/PTU1In8w
Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy associated with Tysabri. http://t.co/KkxC4CaB
FDA approves Voraxaze to treat patients with toxic methotrexate levels. http://t.co/2RXGQ4H5
Register for CDER Small Business Assistance webinar "Electronic Source Documentation in Clinical Trials." http://t.co/7L3VO299
New Drug Safety Podcast for Healthcare Professionals: New Boxed Warning and Contraindication for Adcetris. http://t.co/r4IXymrK
© 2011 Ottosen. All rights reserved.
All site content is provided "as is" and does not represent the views of any organization
